Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 34

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 34
---
 She completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in pulmonary and critical care medicine at the University of Washington.

#### Mirum Pharmaceuticals2025 Proxy Statement29

### TABLE OF CONTENTS
| Executive Compensation |

### Compensation Discussion and Analysis

### Overview
This Compensation Discussion and Analysis discusses our executive compensation policies and how and why our Compensation Committee arrived at specific compensation decisions for the year ending December 31, 2024 for the individuals who served as our principal executive officer, principal financial officer and our two other executive officers as of such date. These individuals are referred to as our “named executive officers” for 2024:

| Chris Peetz             
 Chief Executive Officer |     | Eric Bjerkholt          
 Chief Financial Officer |     | Peter Radovich                        
 President and Chief Operating Officer |     | Joanne Quan, M.D.     
 Chief Medical Officer |

#### Executive Summary
The important features of our executive compensation program include the following:

• A substantial portion of executive pay is tied to performance. We structure a significant portion of our named executive officers’ compensation to be variable, at risk and tied directly to our measurable performance. For 2024, 88.7% of our Chief Executive Officer’s total reported compensation and an average of 82.4% of our other named executive officers’ total reported compensation was linked to performance, consisting of annual performance bonus earned and equity incentives awarded, as reported in the “Fiscal Year 2024 Summary Compensation Table”.

#### FOR CEO

#### FOR NEOs*
| 11.1%Salary            |
| 12.0%Bonus             |
| 18.6%PSUs              |
| 15.1%RSUs              |
| 43.1%Options           |
| 0.2%Other Compensation |

| 17.1%Salary            |
| 12.4%Bonus             |
| 13.6%PSUs              |
| 18.7%RSUs              |
| 37.7%Options           |
| 0.5%Other Compensation |

* The chart includes all NEOs except for the CEO.

#### 30Mirum Pharmaceuticals2025 Proxy Statement

#### TABLE OF CONTENTS

#### Executive Compensation
• Our executive bonuses are dependent on meeting corporate objectives. Our annual performance-based bonus opportunities for all of our named executive officers are dependent upon our achievement of annual corporate objectives established each year and the individual officer’s contributions towards such corporate objectives.

• We emphasize long-term equity incentives. Equity awards